Sufficient high affinity plasminogen activator will be isolated from blood to enable its effect on fibrinogen degradation to be studied. This will include a study of the plama factor which we have identified but not characterized which increases the activity of the plasminogen activator of blood. The hypothesis that conversion of proactivator to activator requires some clotting activity will be tested. The effect of fibrin and fibrinogen on plasmin elaboration by the high affinity plasminogen activator of blood will be tested using a specific fluorescent substrate. Since blood is a relatively poor source of plasminogen activator, other sources such as tissue and cadaver perfusates will be used to isolate sufficient quantity of high affinity activator for radiolabeling. Iodination by chloromine-T will be the initial method used for attaching I125 to the activator. Studies in animals in whom pulmonary emboli have been induced will be undertaken in order to evaluate the in vivo properties of a high affinity activator as a diagnostic and therapeutic agent. Localization by scanning as well as lysis will be compared with that of radiolabeled urokinase.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL023367-07
Application #
3337238
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1982-07-01
Project End
1987-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
7
Fiscal Year
1985
Total Cost
Indirect Cost
Name
St. Elizabeth's Medical Center of Boston
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
Pannell, R; Black, J; Gurewich, V (1988) Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 81:853-9
Dwivedi, C; Pannell, R; Gurewich, V (1988) Fibrin activatable urokinase (FA-UK): a latent form of UK found in urine related to a complex with an inhibitor/fibrin-interacting cofactor. Thromb Res 51:197-208
Gurewich, V (1988) Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action. Semin Thromb Hemost 14:110-5
Gurewich, V; Pannell, R (1987) Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood 69:769-72
Pannell, R; Gurewich, V (1987) Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 69:22-6
Gurewich, V (1987) Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator. J Am Coll Cardiol 10:16B-21B
Pannell, R; Gurewich, V (1986) Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 67:1215-23
Gurewich, V; Pannell, R (1986) A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Thromb Res 44:217-28